Metaplastic Carcinoma of the Breast Is More Aggressive Than Triple-negative Breast Cancer: A Study From a Single Institution and Review of Literature
| Autor: | Xuan Peng, Melissa Hughes, Shicha Kumar, Tolutope Oyasiji, Dima El Zein, Thaer Khoury, Hossam Jabbour |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Adult
0301 basic medicine Oncology Cancer Research medicine.medical_specialty Metaplastic carcinoma Triple Negative Breast Neoplasms Article 03 medical and health sciences 0302 clinical medicine Breast cancer Internal medicine Biomarkers Tumor medicine Humans skin and connective tissue diseases Survival rate Triple-negative breast cancer Aged Metaplasia business.industry Carcinoma Ductal Breast Middle Aged Metaplastic Breast Carcinoma Prognosis medicine.disease Survival Rate 030104 developmental biology 030220 oncology & carcinogenesis Carcinoma Squamous Cell Female Triple-Negative Breast Carcinoma Neoplasm Recurrence Local business Spindle cell carcinoma |
| Zdroj: | Clinical Breast Cancer. 17:382-391 |
| ISSN: | 1526-8209 |
| DOI: | 10.1016/j.clbc.2017.04.009 |
| Popis: | We aimed to describe our experience with metaplastic breast carcinoma (MBC), evaluate its clinical outcome compared with triple-negative breast cancer (TNBC), and provide a through and comprehensive review of the literature to date.We reviewed MBC cases (n = 46) from our institution. The following variables were recorded: tumor histologic subtype, Nottingham grade, tumor size, lymph node status, Tumor, Node, Metastases stage, biomarkers profile, patient's age and race, therapy modality (chemotherapy and radiation), and survival (disease-free survival [DFS] and overall survival [OS]). The clinical and pathological data for TNBC (n = 508) cases were extracted from the breast cancer database. To compare the survival between MBC and TNBC, a subgroup of MBC cases (n = 40) were matched with TNBC cases (n = 40) on the basis of known prognostic confounders.There were 17 of 46 (37%) cases with mesenchymal differentiation, 12 (26.1%) squamous cell carcinoma, 14 (30.4%) spindle cell carcinoma, and 3 (6.5%) mixed type. MBC presented at a more advanced stage than TNBC (P = .014) and was more likely to recur (34% vs. 15.5%; P = .004). More MBC patients died from disease than TNBC (29% vs. 16%; P = .05). In the multivariate analysis, MBC had approximately twice the risk of local recurrence than TNBC (95% confidence interval, 1.01-3.83; P = .05). MBC patients had worse DFS and OS than the matched TNBC patients (P .001 and P = .033, respectively). A review of the literature comparing MBC versus TNBC is presented.Our results suggest that MBC is clinically more aggressive than TNBC. Further studies might help delineate the differences between these 2 entities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect